<DOC>
	<DOCNO>NCT02449031</DOCNO>
	<brief_summary>This multicenter , prospective , two cohort , observational study 5-year period Cystic Fibrosis ( CF ) patient chronic Pseudomonas aeruginosa infection.The study collect data 1 year respiratory function , antibacterial effectiveness , clinical outcome treatment inhale antipseudomonal antibiotic data 5 year microbiological safety assessment .</brief_summary>
	<brief_title>Observational Study Cystic Fibrosis Patients Using TOBI® Podhaler™ Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs</brief_title>
	<detailed_description>This study include CF patient chronically colonize P. aeruginosa enrol Cystic Fibrosis Foundation ( CFF ) PortCF registry use TOBI Podhaler another FDA-approved inhale antipseudomonal antibiotic . No therapeutic intervention assign physician use discretion choose treatment regimen patient . Sputum sample ( primarily collect routine clinical follow-up ) patient able spontaneously produce sputum sent central laboratory analysis . In addition , study include two optional sub-studies qualify patient first study year - Sputum microbiology sub-study TOBI Podhaler sputum pharmacokinetics ( PK ) sub-study .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>≥ 6 year age . Documented FEV1 ≥ 25 % predict previous year . Diagnosis cystic fibrosis . Established diagnosis chronic P. aeruginosa infection lung define two positive P. aeruginosa culture previous year document subject 's medical history ( may include history one positive culture year prior enrollment one positive culture specimen collect baseline visit ) . Prescribed initiate chronic treatment FDAapproved inhale antipseudomonal antibiotic chronic P. aeruginosa infection ( e.g . TOBI Podhaler , TOBI® , Cayston® Bethkis® ) . Actively enrol willingness enroll PortCF registry . Willing able provide write informed consent , parent/guardian consent applicable pediatric assent , participation use relevant clinical data previously capture PortCF . Anticipated good adherence routine visit , define investigator good knowledge patient least 23 routine visit previous year . Documented FEV1 &lt; 25 % predict previous year . Current participation interventional clinical study inhale antibiotic treatment . Treatment compound tobramycin ( e.g . use tobramycin IV solution adapt use inhalation ) . Treatment inhale antipseudomonal antibacterial drug ( ) FDA approve . Patients undergo early eradication regimen CF ( first line therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>